AED evaluated
|
Levetiracetam
|
Zonisamide
|
2
nd
AED
|
PB (14 dogs)
|
PB (8 dogs)
|
PB (15 dogs)
|
PB (33 dogs)
|
PB (11 dogs)
|
PB (33 dogs)
|
-
|
3
rd
AED
|
PBr (14 dogs)
|
PBr (8 dogs)
|
PBr (15 dogs)
|
PBr (29 dogs)
|
PBr (4 dogs)
|
PBr (29 dogs)
|
-
|
4
th
AED
|
-
|
-
|
-
|
Gapa (2 dogs)
|
-
|
Felb (1 dog) or Gaba (1 dog) or Cloraz (1 dog)
|
-
|
No of dogs
|
14
|
8
|
15
|
22
|
11
|
12
|
10
|
Period of treatment (months)
|
2-6 or more
|
Approx. 2-3
|
median, 38; range, 13.8-95.5
|
9 (during the 5th m no AED was administered)
|
range, 4-17
|
mean, 8; median, 9; range, 2 -18
|
median, 12; mean, 11.2
|
Dose of AED(s) (mg/kg)
|
LEV: 10 for 2 m, 20 for further 2 m, 10–20 until 6 m and then 10–20 long-term PO TID; PB and PBr: NA but were within normal reference values
|
LEV: median, 22.15; mean, 21.7; range, 10–32.8 PO TID; PB and PBr: NA but were within normal reference values
|
LEV: range, 7.1-23.8 PO TID; PB and PBr: NA
|
lEV: median, 20.6; range, 17–23.1 PO TID; PB: median, 8.7; range, 2.9-17.2; PBr: median, 39.1; range, 13.6-133.3 PO SID)
|
Zonisamide: mean, 8.9; range, 5–11. PO BID; other AED doses were NA but continued unchanged or reduced
|
Zonisamide: mean, 8.9; range, 5–11. PO BID; other AEDs doses were NA but reduced or eliminated in 9/12 dogs
|
median, 9.5; mean, 8.65; range, 2.5-12 PO BID
|
Pre-treatment SF (seizures/month)
|
median, 7.25; mean 8.2 (recorded over a period of 2 m)
|
median, 8; mean 9.7 +/− 7.6; range 1–25 (period not recorded)
|
mean, 4.3 (recorded over a period of median 17 m)
|
median, 8.4+/−10; mean, 7.6 – 7.6 (recorded over a period of 2 m)
|
median 6.5; range 1–72 (over a period of 4 m)
|
median 19.8; mean 33 (recorded over a period of 2.5 to 82 m)
|
median, 3; mean, 4.4; range, 2–10 (period not recorded)
|
Post-treatment SF (seizures/month)
|
4 m: median 3.5; mean 3.7. 6 m: median 4.25; mean 4.8
|
median, 0; mean 3.9 +/−6; range 0–15.5
|
mean, 1.96
|
mean, 4.4+/−5.2
|
median, 1.63; range, 0-9
|
mean, 1.8; median 3
|
median, 1.5; mean, 2.5; range, 0-10
|
No of dogs that were failures
|
4 m: 2/14 (15%) 6 m: 2/11 (18%)
|
-
|
-
|
-
|
-
|
5/12 (42%)
|
4/10 (40%)
|
No of dogs with >0% - <50% reduction in SF
|
4 m: 3/14 (21%) 6 m: 1/11 (9%)
|
-
|
-
|
-
|
2/10 (20%)
|
-
|
-
|
No of dogs with ≥50% - <100% reduction in SF
|
4 m: 6/14 (43%) 6 m: 7/11 (64%)
|
3/8 (37.5%)
|
15/15 (100%)
|
12/22 (56%)
|
6/10 (60%)
|
5/12 (42%)
|
2/10 (20%)
|
No of dogs with 100% reduction in SF
|
4 m: 3/14 (21%) 6 m: 1/11 (9%)
|
5/8 (62.5%)
|
-
|
4/22 (17%)
|
2/10 (20%)
|
2/12 (16%)
|
4/10 (40%)
|
No of dogs with >30% reduction in SF
|
4 m: 11/14 (79%) 6 m: 8/11 (73%)
|
5/8 (62.5%)
|
15/15 (100%)
|
-
|
8/10 (80%)
|
7/12 (58%)
|
6/10 (60%)
|
95% CI successfully treated cases
|
4 m: 39% - 89%
|
100%
|
100%
|
54% - 92%
|
56% - 100%
|
30% - 86%
|
30% - 90%
|
|
6 m: 50% - 96%
| | | | | | |
Overall evidence for/against recommending the use of an AED
|
Fair evidence for recommending the use of levetiracetamas an an adjunct AED.
|
Insufficient evidence for recommending the use of zonisamide as a monotherapy AED. Insufficient evidence for recommending the use of zonisamide as an adjunct AED.
|